aEkin Mese Say, MD; bGokhan Okan, MD; cGonca Gökdemir, MD aEyup State Hospital, Istanbul, Turkey; bKemerburgaz University, Dermatology Department, Istanbul, Turkey; cBahcesehir University, Dermatology Department, Turkey Disclosure: The authors report
aRichard R. Winkelmann, DO; bJane Yoo, MD, MPH; cNatalie Tucker, BS; dRichard White, MS; eDarrell S. Rigel MD, MS aMelanoma Clinical Research Fellow, Rigel Dermatology, New York, New York; bMohs
aNeal Bhatia, MD; bRadhakrishnan Pillai, PhD aTherapeutics Clinical Research, San Diego, California; aDow Pharmaceutical Sciences Inc. (a division of Valeant Pharmaceuticals), Petaluma, California Disclosure: Dr. Bhatia is a consultant and/or
aPhilip R. Cohen, MD; bE. Victor Ross, MD aDepartment of Dermatology, University of California San Diego, San Diego, California; bDivision of Dermatology, Scripps Clinic, San Diego, California Disclosure: Dr. Cohen
aStacey J. Pilkington, DO; bSarah Belden, DO; aRichard A. Miller, DO aAzeal Dermatology Institute, Boulder, Colorado.; bUniversity Hospitals Regional Hospitals, Traditional Rotating Intern, Richmond Heights, Ohio Disclosure: The authors report
